{
    "nct_id": "NCT06813898",
    "official_title": "ENLIGHTEN: Detection by POSLUMA Following Negative Other PET-PSMA Imaging",
    "inclusion_criteria": "* Men with a history of prostate adenocarcinoma treated with local therapy (including radical prostatectomy or radical prostatectomy and secondary therapy [i.e. salvage radiation])\n* Men must have biochemical recurrence (defined as PSA >= 0.1ng/ml) after therapy\n* PSA < 0.5ng/ml (within 90 days of enrollment)\n* Men must have had negative or equivocal PET PSMA based imaging with 90 days of enrollment with an Food and Drug Administration (FDA) approved non-POSLUMA tracer\n* Non-castrate testosterone (testosterone [T] > 50ng/dL) within 90 days of study entry\n* Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures\n* Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on the study\n* Concurrent diseases and malignancies are permitted\nHealthy volunteers allowed\nMust be MALE",
    "exclusion_criteria": "* Most recent PSA not between 0.1ng/ml and 0.5ng/ml\n* Men with non-metastatic castrate resistant prostate cancer (defined as rising PSA and T < 50ng/dl)\n* Patients receiving 5-alpha reductase inhibitors, androgen deprivation therapy and androgen receptor antagonists within 3 months of enrollment (men may start these therapies at physician discretion immediately following POSLUMA PET PSMA scan)",
    "miscellaneous_criteria": ""
}